S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price & News

$2.74
+0.04 (+1.48%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.66
$2.81
50-Day Range
$2.31
$3.49
52-Week Range
$1.31
$3.79
Volume
3.72 million shs
Average Volume
3.08 million shs
Market Capitalization
$520.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
155.0% Upside
$7.00 Price Target
Short Interest
Bearish
3.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Lexicon Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

717th out of 983 stocks

Pharmaceutical Preparations Industry

358th out of 486 stocks


LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

Why Lexicon Pharmaceuticals Stock Crashed This Week
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Q1 2023 Lexicon Pharmaceuticals Inc Earnings Call
See More Headlines

LXRX Price History

LXRX Company Calendar

Last Earnings
11/03/2021
Today
6/04/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+155.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-101,940,000.00
Net Margins
-87,620.63%
Pretax Margin
-87,620.63%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
$0.46 per share

Miscellaneous

Free Float
176,672,000
Market Cap
$520.34 million
Optionable
Optionable
Beta
1.28

Social Links


Key Executives

  • Lonnel Coats
    Chief Executive Officer & Director
  • Jeffrey L. Wade
    President & Chief Financial Officer
  • Craig B. Granowitz
    Chief Medical Officer & Senior Vice President
  • Brian T. Crum
    Secretary, Senior Vice President & General Counsel
  • Kiernan A. Seth
    Chief Commercial Officer & Vice President













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2023?

3 equities research analysts have issued twelve-month target prices for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $3.00 to $10.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 155.0% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2023?

Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of 2023. Since then, LXRX stock has increased by 43.7% and is now trading at $2.7450.
View the best growth stocks for 2023 here
.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 6,450,000 shares, an increase of 30.8% from the April 30th total of 4,930,000 shares. Based on an average trading volume of 756,900 shares, the days-to-cover ratio is presently 8.5 days.
View Lexicon Pharmaceuticals' Short Interest
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 105.14% and a negative net margin of 87,620.63%. During the same quarter in the prior year, the firm posted $0.71 earnings per share.

What ETFs hold Lexicon Pharmaceuticals' stock?

ETFs with the largest weight of Lexicon Pharmaceuticals (NASDAQ:LXRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.98%), FMR LLC (2.76%), JPMorgan Chase & Co. (1.74%), Pinnacle Associates Ltd. (1.03%), Geode Capital Management LLC (0.91%) and State Street Corp (0.83%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends
.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.75.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $520.34 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -